Rewriting AML's Destiny: Ziftomenib's Promise to Shine at EHA 2025
- Milan Spotlight: Kura Oncology and Kyowa Kirin are set to unveil pivotal updated data on ziftomenib in combination with chemotherapy for Acute Myeloid Leukemia (AML) at the 2025 European Hematology Association (EHA) Congress.
- Targeting a Killer: New findings from the KOMET-007 trial focus on ziftomenib's impact on newly diagnosed AML patients with specific, challenging genetic mutations (NPM1-mutant or KMT2A-rearranged)1, 2.
- A New Dawn in AML?: The oral presentation could signal a significant leap forward, offering fresh hope in the relentless battle against this aggressive blood cancer.
The fight against Acute Myeloid Leukemia (AML) is poised for a dramatic development as the global hematology community turns its gaze to Milan. This June, Kura Oncology and Kyowa Kirin will present crucial updated clinical data from the KOMET-007 trial at the highly anticipated 2025 European Hematology Association (EHA) Congress7. The focus is squarely on ziftomenib, a pioneering once-daily, oral menin inhibitor, when combined with the standard intensive chemotherapy regimen (7+3) in newly diagnosed AML patients.
This investigational therapy targets the very mechanisms that drive AML, particularly in patients with NPM1 mutations or KMT2A rearrangements, by inhibiting the menin-KMT2A interaction and promoting the differentiation of leukemia cells2, 3. Having already received Breakthrough Therapy Designation from the U.S. FDA for certain AML patients, the anticipation for these updated results is palpable. The oral presentation, scheduled for Thursday, June 12th, will delve into data from both dose-escalation and expansion portions of the KOMET-007 trial. As Kura’s Chief Medical Officer, Dr. Mollie Leoni, expressed, these findings strengthen confidence in ziftomenib's potential to become a vital treatment option. This EHA showcase is a critical step, underscoring the momentum towards the upcoming pivotal Phase 3 KOMET-017 trial and a new era of hope for the AML community. Abstracts are currently available on the EHAweb.org website, and full presentation materials will be accessible on Kura's website post-congress.